The COPD Foundation, along with global partners, surveyed people with chronic respiratory disease. The survey gave the patient community a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions.

1,196 People with respiratory disease surveyed

70% were “bothered” or “really bothered” by a tobacco company making an inhaler to treat lung conditions.

Respondent Information

Survey language
- English: 86.4%
- German: 2.2%
- Spanish: 11.4%

Reported Conditions
- COPD: 78.1%
- Emphysema: 45.2%
- Asthma: 37.6%
- Bronchiectasis: 36.6%
- Other*: 9.1%
- Unsure/prefer not to answer: 2.7%

Former smoker: 73.1%
- Never smoked: 14.9%
- Current smoker: 11.1%

Willing to switch to a treatment that tobacco companies do not fund
- Yes: 48%
- No: 35%
- Unsure/no answer: 17%

The COPD Foundation believes patients deserve and desire the right for transparency about their medications. Shared decision making between patients and clinicians will allow for choosing the best plan for each individual.

Notes:
- Complete survey was only available to those who indicated inhaler use. Reported conditions may include multiple selections by respondents. *Other includes: Alpha-1 antitrypsin deficiency, N/A lung diseases, ILD, IDPA, etc.